Literature DB >> 27108013

Cumulative incidence of tuberculosis in lung cancer patients in Japan: A 6-year observational study.

Yuzo Suzuki1, Shiro Imokawa2, Jun Sato3, Tomohiro Uto4, Takafumi Suda5.   

Abstract

BACKGROUND: Tuberculosis (TB) remains a health-related problem worldwide, and certain malignancies are known to be associated with an increased risk of TB. Lung cancer is the leading cause of cancer-related death, and the number of patients with lung cancer has been reportedly increasing. As the prognosis of lung cancer remains poor, aggressive comprehensive therapies have been used. The immunosuppression caused by cancer itself and treatment-associated immune modulation may increase the risk of TB. The present study was conducted to investigate the cumulative incidence of TB in lung cancer patients.
METHODS: This observational study included 904 consecutive patients diagnosed with histologically confirmed lung cancer from March 2007 to March 2013 and followed until March 2015 (mean 25.2 months). The cumulative incidence of TB was estimated using the Kaplan-Meier method.
RESULTS: Nine lung cancer patients (1.00%) developed TB during the observation period. In all cases, TB occurred within 2 years of the diagnosis of lung cancer. The cumulative incidence of TB at 6 months, 1 year, and 2 years was 0.65%, 1.15%, and 1.38%, respectively.
CONCLUSIONS: The cumulative incidence of TB in lung cancer patients was 1.38% in Japan.
Copyright © 2015 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cumulative incidence; Lung cancer; Tuberculosis

Mesh:

Year:  2015        PMID: 27108013     DOI: 10.1016/j.resinv.2015.11.001

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


  4 in total

1.  Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis.

Authors:  Claudia C Dobler; Kelvin Cheung; John Nguyen; Andrew Martin
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

2.  Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with Mycobacterium tuberculosis.

Authors:  Kenji Nakahama; Hiroyasu Kaneda; Koichi Ogawa; Yoshiya Matsumoto; Yoko Tani; Tomohiro Suzumura; Shigeki Mitsuoka; Tetsuya Watanabe; Kazuhisa Asai; Tomoya Kawaguchi
Journal:  Intern Med       Date:  2022-04-01       Impact factor: 1.282

3.  Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis.

Authors:  Akio Sakamoto; Manato Yamashita; Yuta Hori; Takeshi Okamoto; Atsushi Shimizu; Shuichi Matsuda
Journal:  Am J Case Rep       Date:  2017-10-24

4.  Risk of active tuberculosis in migrants diagnosed with cancer: a retrospective cohort study in British Columbia, Canada.

Authors:  Divjot S Kumar; Lisa A Ronald; Kamila Romanowski; Caren Rose; Hennady P Shulha; Victoria J Cook; James C Johnston
Journal:  BMJ Open       Date:  2021-03-02       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.